The life sciences sector (and biotechnology in particular) has emerged
as a prospective area, and attracted a lot of attention recently.
Multinational companies in the life sciences seek to explore new
markets, and, on the other side, governments strive to develop the life
sciences sector perceiving it as a basis for long-term development.
Whilst the R&D activities of global multinationals in life sciences
still remain concentrated in the Triadic economies, these companies
increasingly seek for new location to tap the knowledge. New EU member
states emerge as such prospective locations. Notwithstanding the
interest towards this sector, the body of literature on the development
of life sciences in new EU member states, and particularly, the role of
multinational companies, remains scant. In this explorative study we
attempt to fill this gap and focus on the role of multinational
companies in the Czech life sciences sector.
JEL codes: F21 F23 L65 O32
Keywords: life sciences; biotechnology; pharmaceuticals; multinational companies; EU
UNU-MERIT Working Papers ISSN 1871-9872